The Hallmarks of Aging: A Research Framework
Lopez-Otin et al.'s landmark 2013 paper (updated 2023) defined the hallmarks of aging as:
- Genomic instability
- Telomere attrition
- Epigenetic alterations
- Loss of proteostasis
- Disabled macroautophagy
- Deregulated nutrient sensing
- Mitochondrial dysfunction
- Cellular senescence
- Stem cell exhaustion
- Altered intercellular communication
- Chronic inflammation (inflammaging)
- Dysbiosis
No single peptide addresses all hallmarks. The rationale for multi-agent longevity research is covering the largest number of mechanistically distinct hallmarks with the smallest agent count. This guide addresses a 4-agent protocol covering hallmarks 2, 3, 4, 7, 8, 10, and 11.
The Four-Agent Protocol
Agent 1: Epithalon 50mg
Hallmarks addressed: Telomere attrition (#2), epigenetic alterations (#3), altered intercellular communication (#10)
Epithalon is the only research peptide with published evidence for direct telomerase activation in somatic cells. Its transcriptional mechanism (hTERT promoter activity, DNA methylation changes) places it squarely in hallmarks 2 and 3. Melatonin restoration addresses intercellular signaling via circadian/pineal axis.
Agent 2: GHK-Cu 50mg
Hallmarks addressed: Loss of proteostasis (#4), cellular senescence (#8), chronic inflammation (#11)
GHK-Cu's 300+ gene network includes chaperone upregulation (proteostasis), SASP reduction (anti-senescence), and comprehensive anti-inflammatory gene modulation.
Agent 3: NAD+ 500mg
Hallmarks addressed: Mitochondrial dysfunction (#7), deregulated nutrient sensing (#6), genomic instability (#1)
NAD+ restoration via supplementation restores sirtuin activity (SIRT1-7), which regulates mitochondrial biogenesis (PGC-1alpha), insulin sensitivity (FOXO/mTOR signaling), and DNA repair capacity (PARP support).
Agent 4: BPC-157 10mg
Hallmarks addressed: Chronic inflammation (#11), altered intercellular communication (#10), stem cell exhaustion (#9)
BPC-157's NO system modulation and growth factor receptor upregulation supports tissue homeostasis, reduces systemic inflammation through gut-barrier protection, and supports stem cell niche maintenance.
Hallmark Coverage Map
| Hallmark | Epithalon | GHK-Cu | NAD+ | BPC-157 |
|---|---|---|---|---|
| Telomere attrition | Direct | -- | SIRT1/chromatin | -- |
| Epigenetic alterations | Direct | Partial | SIRT1 | -- |
| Loss of proteostasis | -- | Chaperones | SIRT2 | -- |
| Mitochondrial dysfunction | Indirect | Indirect | Direct | -- |
| Cellular senescence | Partial | Direct | SIRT1/p53 | -- |
| Intercellular communication | Melatonin | SASP reduction | -- | NO/VEGF |
| Chronic inflammation | IL-6/TNF-alpha | NF-kB, IL-6 | CD38/PARP | iNOS/NF-kB |
Coverage: 9 of 12 hallmarks with at least one agent
Research Protocol Design
Sequencing Rationale
Phase 1 (Baseline establishment): 4 weeks with no treatment. Establish baseline telomere length, NAD+/NADH ratio, senescence markers, inflammatory cytokines.
Phase 2 (NAD+ restoration): Weeks 1-4 of treatment. NAD+ first to establish improved cellular energy state.
Phase 3 (Add Epithalon): Weeks 5-14 (10-day course). Transcriptional effects require cellular energy — pre-loading NAD+ may improve hTERT response.
Phase 4 (Add GHK-Cu): Weeks 15-24. ECM and anti-inflammatory effects become most relevant after initial genomic stabilization.
Phase 5 (Add BPC-157): Ongoing from week 10. Gut homeostasis benefits accumulate continuously.
Endpoint Battery for Full-Stack Research
Genomic/Telomere:
- Telomere length (RTL qPCR)
- hTERT expression (RT-qPCR)
- gamma-H2AX foci (DNA damage marker)
Metabolic/Mitochondrial:
- NAD+/NADH ratio (enzymatic assay)
- SIRT1 deacetylase activity
- Mitochondrial membrane potential (JC-1)
- ATP production rate
Inflammation/Senescence:
- IL-6, IL-8, TNF-alpha, MCP-1 (multiplex ELISA)
- p16INK4a, p21 expression
- SA-beta-galactosidase staining
ECM/Tissue:
- Collagen I/III ratio
- MMP-1, MMP-3, TIMP-1 expression
All four agents available from our verified supplier — for laboratory research only.